Interview with Daniel Carcillo

GUYS. IT HAPPENED. Cathie Wood and ARK Invest have invested in a Psychedelic Stock! Specifically, ARKG, or the ARK Genomic Revolution ETF have purchased atai Life Sciences (Nasdaq: atai)!

Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight

Follow us on Instagram:
@psycbiz
@psycspotlight

To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/

Last year, the Psychedelic Investor and the Reddit Page “ShroomStocks” managed to get the question of “would you ever invest in Psychedelic Stocks” asked to Cathie Wood of ARK Invest, and her answer was a dismissive NO. She said that ARK did not invest in binary stocks, though Kevin O’Leary, who was on the same panel disagreed.

Well, it seems that time (and maybe Kevin O’Leary) have changed her mind. On Wednesday, February 9th, it was revealed that the Ark Genomic Revolution ETF, ticker symbol ARKG, had purchased 83,278 shares of ATAI.

And while this only represents 0.01% of that fund’s total holdings, it does represent a big moment for the entire psychedelics industry. For better or worse, Cathie Wood has a huge voice among investors who like growth stocks, and next-generation technology stocks, which psychedelic stocks definitely represent.

This will likely put more focus, not only on atai, but the entire psychedelics sector. I would not be surprised if companies such as MindMed (MMEDF) and Cybin (CYBN) also benefit from this. Perhaps, in the future, Ark will also buy these companies.

Hopefully, this is but an opening position, and ARKG continues to buy psychedelic stocks such as atai and MindMed. Ideally, I would also like to see the flagship ETF, ARKK, also invest in psychedelic Stocks.

#CathieWood #ARKG #PsychedelicStocks